JP2013523746A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523746A5 JP2013523746A5 JP2013502706A JP2013502706A JP2013523746A5 JP 2013523746 A5 JP2013523746 A5 JP 2013523746A5 JP 2013502706 A JP2013502706 A JP 2013502706A JP 2013502706 A JP2013502706 A JP 2013502706A JP 2013523746 A5 JP2013523746 A5 JP 2013523746A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- phenyl
- oxadiazol
- benzimidazol
- dgat1 inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940127193 DGAT1 inhibitor Drugs 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 26
- 150000002148 esters Chemical class 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 208000011580 syndromic disease Diseases 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 206010060755 Type V hyperlipidaemia Diseases 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 150000003626 triacylglycerols Chemical class 0.000 claims description 12
- 208000016667 Familial chylomicronemia syndrome Diseases 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 230000000291 postprandial effect Effects 0.000 claims description 7
- 208000010201 Exanthema Diseases 0.000 claims description 6
- -1 N-methylpiperidinyl group Chemical group 0.000 claims description 6
- 206010048214 Xanthoma Diseases 0.000 claims description 6
- 206010048215 Xanthomatosis Diseases 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 230000008021 deposition Effects 0.000 claims description 6
- 201000005884 exanthem Diseases 0.000 claims description 6
- 206010019847 hepatosplenomegaly Diseases 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 206010037844 rash Diseases 0.000 claims description 6
- 230000000306 recurrent effect Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 230000006735 deficit Effects 0.000 claims description 5
- GXALXAKNHIROPE-UHFFFAOYSA-N 2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetic acid Chemical group C1CC(CC(=O)O)CCC1C1=CC=C(C=2N=CC(NC=3C=NC(=CC=3)C(F)(F)F)=CC=2)C=C1 GXALXAKNHIROPE-UHFFFAOYSA-N 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 2
- UBGWQKWLRPICHU-UHFFFAOYSA-N 2-[3,5-dichloro-4-[6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-1h-benzimidazol-2-yl]phenoxy]acetic acid Chemical compound ClC1=CC(OCC(=O)O)=CC(Cl)=C1C1=NC2=CC=C(C=3OC(=NN=3)C=3C=CC(Cl)=CC=3)C=C2N1 UBGWQKWLRPICHU-UHFFFAOYSA-N 0.000 claims description 2
- SSCBDEUAEZBUIJ-UHFFFAOYSA-N 2-[4-[6-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-1h-benzimidazol-2-yl]-3,5-dimethylphenoxy]acetic acid Chemical compound CC1=CC(OCC(O)=O)=CC(C)=C1C1=NC2=CC=C(C=3OC(=NN=3)C=3C=CC(Cl)=CC=3)C=C2N1 SSCBDEUAEZBUIJ-UHFFFAOYSA-N 0.000 claims description 2
- TUBPDBIOKLNJTG-UHFFFAOYSA-N 3-[4-[6-(5-methoxy-1,3,4-oxadiazol-2-yl)-1h-indol-2-yl]-3,5-dimethylphenyl]propanoic acid Chemical compound O1C(OC)=NN=C1C1=CC=C(C=C(N2)C=3C(=CC(CCC(O)=O)=CC=3C)C)C2=C1 TUBPDBIOKLNJTG-UHFFFAOYSA-N 0.000 claims description 2
- DZTVXQZHWYUNLE-UHFFFAOYSA-N 3-[4-[6-[5-(4-methoxyanilino)-1,3,4-oxadiazol-2-yl]-1h-benzimidazol-2-yl]-3,5-dimethylphenyl]propanoic acid Chemical compound C1=CC(OC)=CC=C1NC1=NN=C(C=2C=C3NC(=NC3=CC=2)C=2C(=CC(CCC(O)=O)=CC=2C)C)O1 DZTVXQZHWYUNLE-UHFFFAOYSA-N 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000006267 biphenyl group Chemical group 0.000 claims description 2
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- MUZRGKSNUTWRAF-BHQIMSFRSA-M chembl2364625 Chemical group [Na+].C1C[C@@H](CC(=O)[O-])CC[C@@H]1C1=CC=C(C=2N=CC(NC=3C=NC(=CC=3)C(F)(F)F)=CC=2)C=C1 MUZRGKSNUTWRAF-BHQIMSFRSA-M 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000003003 spiro group Chemical group 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical group OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001227 hypertriglyceridemic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007106 neurocognition Effects 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 206010033645 Pancreatitis Diseases 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31881410P | 2010-03-30 | 2010-03-30 | |
| US61/318,814 | 2010-03-30 | ||
| PCT/US2011/030234 WO2011123401A1 (en) | 2010-03-30 | 2011-03-29 | Uses of dgat1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016114803A Division JP6251321B2 (ja) | 2010-03-30 | 2016-06-08 | Ｄｇａｔ１阻害剤の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013523746A JP2013523746A (ja) | 2013-06-17 |
| JP2013523746A5 true JP2013523746A5 (https=) | 2014-05-15 |
Family
ID=44170024
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013502706A Withdrawn JP2013523746A (ja) | 2010-03-30 | 2011-03-29 | Ｄｇａｔ１阻害剤の使用 |
| JP2016114803A Active JP6251321B2 (ja) | 2010-03-30 | 2016-06-08 | Ｄｇａｔ１阻害剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016114803A Active JP6251321B2 (ja) | 2010-03-30 | 2016-06-08 | Ｄｇａｔ１阻害剤の使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9061012B2 (https=) |
| EP (1) | EP2552441B1 (https=) |
| JP (2) | JP2013523746A (https=) |
| KR (1) | KR20130073884A (https=) |
| CN (1) | CN102834099B (https=) |
| AU (1) | AU2011235301B2 (https=) |
| BR (1) | BR112012024618A2 (https=) |
| CA (1) | CA2792269A1 (https=) |
| CL (1) | CL2012002716A1 (https=) |
| ES (1) | ES2586127T3 (https=) |
| MA (1) | MA34097B1 (https=) |
| MX (1) | MX2012011333A (https=) |
| NZ (1) | NZ602125A (https=) |
| PH (1) | PH12012501859A1 (https=) |
| RU (1) | RU2012145950A (https=) |
| SG (1) | SG183529A1 (https=) |
| TN (1) | TN2012000458A1 (https=) |
| TW (1) | TW201136916A (https=) |
| WO (1) | WO2011123401A1 (https=) |
| ZA (1) | ZA201206456B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
| BR112014026910A8 (pt) * | 2012-04-25 | 2018-01-09 | Handok Pharmaceuticals Co Ltd | novo derivado de beta-alanina, seus sais farmaceuticamente aceitáveis, e composições farmacêuticas compreendendo o mesmo como ingrediente ativo. |
| WO2013169648A1 (en) | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
| AU2014216137B2 (en) | 2013-02-14 | 2018-05-10 | Ionis Pharmaceuticals, Inc. | Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations |
| DK2991656T3 (da) | 2013-05-01 | 2020-03-23 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression |
| PT3119384T (pt) | 2014-03-20 | 2018-12-12 | Cymabay Therapeutics Inc | Tratamento de doenças colestáticas intra-hepáticas |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| EA201790091A1 (ru) * | 2014-06-26 | 2017-07-31 | Саймабэй Терапьютикс, Инк. | Лечение тяжелой гипертриглицеридемии |
| WO2016181409A1 (en) | 2015-05-11 | 2016-11-17 | Cadila Healthcare Limited | Saroglitazar magnesium for the treatment of chylomicronemia syndrome - |
| WO2017064635A2 (en) | 2015-10-14 | 2017-04-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| IL277332B2 (en) | 2018-03-16 | 2025-01-01 | Anji Pharmaceuticals Inc | Preparations and methods for treating severe constipation |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN113365643A (zh) * | 2018-11-30 | 2021-09-07 | Hdl治疗公司 | 用于治疗包括黄色瘤、颈动脉狭窄和脑动脉粥样硬化的脂质相关疾病的方法 |
| JP2021001143A (ja) * | 2019-06-21 | 2021-01-07 | 小林製薬株式会社 | 乳び血漿改善剤 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3225997A (en) | 1996-05-30 | 1998-01-05 | Trustees Of Columbia University In The City Of New York, The | Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof |
| US6344548B1 (en) | 1998-06-24 | 2002-02-05 | The Regents Of The University Of California | Diacylglycerol o-acyltransferase |
| US20030167483A1 (en) | 1998-06-24 | 2003-09-04 | Farese Robert V. | Diacylglycerol O-acyltransferase |
| US20030154504A1 (en) | 1998-06-24 | 2003-08-14 | Farese Robert V. | Methods and compositions for modulating carbohydrate metabolism |
| WO1999067268A1 (en) | 1998-06-24 | 1999-12-29 | The Regents Of The University Of California | Diacylglycerol o-acyltransferase |
| US6100077A (en) | 1998-10-01 | 2000-08-08 | The Trustees Of Columbia University In The City Of New York | Isolation of a gene encoding diacylglycerol acyltransferase |
| US6444427B1 (en) | 2000-07-11 | 2002-09-03 | The Regents Of The University Of California | Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof |
| JP4164645B2 (ja) | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Ｄｇａｔ阻害剤 |
| KR100772297B1 (ko) | 2002-11-22 | 2007-11-02 | 니뽄 다바코 산교 가부시키가이샤 | 융합 비시클릭 질소-함유 헤테로사이클 |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
| DE10331202A1 (de) * | 2003-07-10 | 2005-03-31 | S.K. Enterprise Gmbh | Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms |
| EP1653969A4 (en) | 2003-08-07 | 2006-12-20 | Japan Tobacco Inc | PYRROLO 1,2-B PYRIDAZINE DERIVATIVES |
| GB0325192D0 (en) | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
| JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
| EP1718309A2 (en) | 2004-01-30 | 2006-11-08 | Japan Tobacco, Inc. | Anorectic compounds |
| WO2006004200A1 (ja) | 2004-07-02 | 2006-01-12 | Sankyo Company, Limited | ウレア誘導体 |
| JP2006045209A (ja) | 2004-07-02 | 2006-02-16 | Sankyo Co Ltd | ウレア誘導体 |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| JP2008516978A (ja) | 2004-10-15 | 2008-05-22 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満症の処置のためのビフェニル−４−イル−カルボニルアミノ酸誘導体の製造および使用 |
| US7795283B2 (en) | 2004-12-14 | 2010-09-14 | Astrazeneca Ab | Oxadiazole derivative as DGAT inhibitors |
| JP2006166742A (ja) * | 2004-12-14 | 2006-06-29 | Japan Health Science Foundation | 高トリグリセリド血症の成因となる２種類のリポタンパクリパーゼ（ｌｐｌ）遺伝子変異及びそれを利用した高トリグリセリド血症を診断するためのｌｐｌ変異検出キット |
| EP2402320A1 (en) * | 2006-03-31 | 2012-01-04 | Novartis AG | Anorectic agents |
| AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| MX2010010471A (es) * | 2008-03-26 | 2010-10-20 | Daiichi Sankyo Co Ltd | Derivado de tetrahidroisoquinolina novedoso. |
-
2011
- 2011-03-29 MA MA35264A patent/MA34097B1/fr unknown
- 2011-03-29 TW TW100110831A patent/TW201136916A/zh unknown
- 2011-03-29 EP EP11715329.6A patent/EP2552441B1/en active Active
- 2011-03-29 WO PCT/US2011/030234 patent/WO2011123401A1/en not_active Ceased
- 2011-03-29 AU AU2011235301A patent/AU2011235301B2/en not_active Ceased
- 2011-03-29 MX MX2012011333A patent/MX2012011333A/es active IP Right Grant
- 2011-03-29 CA CA2792269A patent/CA2792269A1/en not_active Abandoned
- 2011-03-29 CN CN201180016229.9A patent/CN102834099B/zh not_active Expired - Fee Related
- 2011-03-29 ES ES11715329.6T patent/ES2586127T3/es active Active
- 2011-03-29 SG SG2012063848A patent/SG183529A1/en unknown
- 2011-03-29 BR BR112012024618A patent/BR112012024618A2/pt not_active IP Right Cessation
- 2011-03-29 PH PH1/2012/501859A patent/PH12012501859A1/en unknown
- 2011-03-29 JP JP2013502706A patent/JP2013523746A/ja not_active Withdrawn
- 2011-03-29 RU RU2012145950/15A patent/RU2012145950A/ru not_active Application Discontinuation
- 2011-03-29 US US13/637,372 patent/US9061012B2/en active Active
- 2011-03-29 KR KR1020127028214A patent/KR20130073884A/ko not_active Withdrawn
- 2011-03-29 NZ NZ602125A patent/NZ602125A/en not_active IP Right Cessation
-
2012
- 2012-08-28 ZA ZA2012/06456A patent/ZA201206456B/en unknown
- 2012-09-24 TN TNP2012000458A patent/TN2012000458A1/en unknown
- 2012-09-28 CL CL2012002716A patent/CL2012002716A1/es unknown
-
2016
- 2016-06-08 JP JP2016114803A patent/JP6251321B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523746A5 (https=) | ||
| RU2012145950A (ru) | Применения ингибиторов dgati | |
| JP2023159114A (ja) | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 | |
| AU2006212772B2 (en) | Combination of organic compounds | |
| JP2011207898A (ja) | バルサルタンおよびｎｅｐ阻害剤を含む医薬組成物 | |
| JP2021530513A5 (https=) | ||
| SI2303270T1 (en) | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | |
| NZ510209A (en) | Method for treating diabetes, insulin resistance, hyperglycaemia, elevated fatty acids, or hypertriglyceridemia with an aP2 inhibitor in combination with another antidiabetic agent | |
| JP2017523219A5 (https=) | ||
| JP2024095711A (ja) | 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール | |
| JP2008512486A (ja) | 有機化合物の組み合わせ | |
| KR20080066776A (ko) | 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물 | |
| Gu et al. | Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present) | |
| JP2002506024A (ja) | 急性冠動脈虚血症候群および関連状態に対する併用療法および組成物 | |
| TW200306853A (en) | Therapeutic agent for glomerular disease | |
| JP7708760B2 (ja) | 化合物及びα１－アンチトリプシン欠損症の治療のためのそれらの使用 | |
| JP6761346B2 (ja) | 脂質異常症治療剤 | |
| CN105008337A (zh) | 具有改善的体内功效的作为nep抑制剂的取代的联苯基丁酸衍生物 | |
| US20100056460A1 (en) | Combination of organic compounds | |
| JP6976577B2 (ja) | ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤 | |
| RU2809222C2 (ru) | Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия | |
| HK1237263A1 (en) | Dyslipidemia therapeutic agent |